Upgrade to SI Premium - Free Trial

ImmunityBio (IBRX)

6.92 -0.37 (5.08%)

Chart
Today 6M 1Y 5Y

Upcoming Events

- Earnings (8/12/26)

Latest Headlines

Form 4 ImmunityBio, Inc. For: Jun 04 Filed by: Simon Barry J. June 5, 2026 5:30 PM - SEC Filing Form 144 ImmunityBio, Inc. Filed by: Simon Barry J. June 4, 2026 11:03 AM - SEC Filing ImmunityBio to present cancer drug data at ASCO 2026 meeting June 1, 2026 1:53 PM - StreetInsider ImmunityBio Presents New Clinical and Comparative Data Across Lung and Bladder Cancer at ASCO 2026 June 1, 2026 1:52 PM - BizWire ImmunityBio presents UK patient survey on bladder cancer treatment preferences May 22, 2026 7:30 AM - StreetInsider ImmunityBio shows cost savings for ANKTIVA plus BCG versus TAR-200 May 22, 2026 7:30 AM - StreetInsider ImmunityBio Highlights Patient Survey Data at ISPOR 2026 Showing Majority of UK Adults Living with NMIBC Favor Bladder Preservation May 22, 2026 7:30 AM - BizWire ImmunityBio Presents Health Economic Analysis at ISPOR 2026 Showing ANKTIVA® Plus BCG Delivers Lower Cost per Sustained Complete Response Versus TAR-200 in BCG-Unresponsive NMIBC CIS May 22, 2026 7:30 AM - BizWire ImmunityBio, Inc. Securities Fraud Class Action Result of FDA Warning and 21% Stock Decline - Investors may Contact Lewis Kahn, Esq, at Kahn Swick & Foti, LLC May 21, 2026 4:30 PM - StreetInsider ImmunityBio, Inc. Securities Fraud Class Action Result of FDA Warning and 21% Stock Decline - Investors May Contact Lewis Kahn, Esq, at Kahn Swick & Foti, LLC May 20, 2026 2:19 PM - StreetInsider ImmunityBio gets FDA acceptance for ANKTIVA bladder cancer filing May 19, 2026 8:30 PM - StreetInsider ImmunityBio Announces FDA Acceptance of Supplemental BLA for ANKTIVA® Plus BCG in BCG-Unresponsive Non-Muscle Invasive Bladder Cancer with Papillary Disease; PDUFA Date Set for January 6, 2027 May 19, 2026 8:30 PM - BizWire ImmunityBio, Inc. Securities Fraud Class Action Result of FDA Warning and 21% Stock Decline - Investors may Contact Lewis Kahn, Esq, at Kahn Swick & Foti, LLC May 19, 2026 2:18 PM - StreetInsider ImmunityBio presents bladder cancer treatment comparison data at AUA May 19, 2026 7:31 AM - StreetInsider ImmunityBio Presents Favorable Comparative Effectiveness Data in Complete Response Rates of NAI + BCG Versus Nadofaragene and TAR-200 at AUA 2026 May 19, 2026 7:30 AM - BizWire Form 8-K ImmunityBio, Inc. For: May 14 May 18, 2026 5:21 PM - SEC Filing $IBRX DEADLINE: Immunitybio Inc. Investors Who Lost Money Should Contact Block & Leviton Before May 26th Deadline May 18, 2026 3:04 PM - StreetInsider ImmunityBio, Inc. Securities Fraud Class Action Result of FDA Warning and 21% Stock Decline - Investors May Contact Lewis Kahn, Esq, at Kahn Swick & Foti, LLC May 18, 2026 1:03 PM - StreetInsider ImmunityBio receives five US patents for cancer drug combination May 18, 2026 7:31 AM - StreetInsider ImmunityBio Announces Comprehensive U.S. Patents Covering Combination of ANKTIVA with BCG for Cancer Treatment, with Terms Through 2035 May 18, 2026 7:30 AM - BizWire ImmunityBio signs exclusive US deal for Tokyo BCG strain to address shortage May 16, 2026 1:35 PM - StreetInsider ImmunityBio Signs Exclusive U.S. Agreement with Japan BCG Laboratory for the Tokyo Strain of BCG to Enhance BCG Supply in the United States May 16, 2026 1:35 PM - BizWire IBRX Lawsuit Alleges Company Allegedly Violated FDA Drug Rules - ImmunityBio Investors Face Losses Following Company Allegedly Violated FDA Drug Rules: SueWallSt May 7, 2026 9:00 AM - PR NewsWire ImmunityBio, Inc. (IBRX) Misses Q1 EPS by 55c May 7, 2026 7:39 AM - StreetInsider Form 10-Q ImmunityBio, Inc. For: Mar 31 May 7, 2026 7:37 AM - SEC Filing Form 8-K ImmunityBio, Inc. For: May 07 May 7, 2026 7:33 AM - SEC Filing ImmunityBio Reports Record Q1 2026 Results: Net Product Revenue Increased Nearly 2.7x Year-Over-Year to $44 Million in Q1 2026 Expanding on the 2025 Full Year 700% Year-Over-Year Revenue Growth; Cash May 7, 2026 7:30 AM - BizWire ImmunityBio to Present New Comparative Data, Scientific Advances in Non-Muscle Invasive Bladder Cancer CIS and an Update on BCG Naïve Registrational Trial at American Urological Association Annual Me May 5, 2026 7:30 AM - BizWire Form ARS ImmunityBio, Inc. For: Dec 31 April 30, 2026 6:10 AM - SEC Filing Form DEF 14A ImmunityBio, Inc. For: Jun 09 April 30, 2026 6:10 AM - SEC Filing Form DEFA14A ImmunityBio, Inc. April 30, 2026 6:10 AM - SEC Filing ImmunityBio launches ANKTIVA cancer treatment in Saudi Arabia April 21, 2026 7:30 AM - StreetInsider ImmunityBio Announces ANKTIVA® Is Now Available in Saudi Arabia for Bladder and Lung Cancer Patients; Market Entry Achieved Within Two Months of MENA Partnership April 21, 2026 7:30 AM - BizWire Form 8-K ImmunityBio, Inc. For: Apr 09 April 9, 2026 7:39 AM - SEC Filing ImmunityBio reports Q1 revenue of $44 million, up 168% year-over-year April 9, 2026 7:31 AM - StreetInsider ImmunityBio Reports Net Product Revenue Increased Nearly 2.7 Times Year-Over-Year to Record $44 Million in Q1 2026 and $381 Million in Cash and Marketable Securities April 9, 2026 7:30 AM - BizWire Form 8-K ImmunityBio, Inc. For: Apr 06 April 6, 2026 8:03 AM - SEC Filing ImmunityBio responds to FDA concerns over promotional materials April 6, 2026 7:30 AM - StreetInsider ImmunityBio Addresses FDA Correspondence and Reaffirms Commitment to Advertising Compliance April 6, 2026 7:30 AM - BizWire Form 4 ImmunityBio, Inc. For: Mar 31 Filed by: SOON-SHIONG PATRICK April 2, 2026 8:09 PM - SEC Filing Form 8-K ImmunityBio, Inc. For: Mar 30 March 31, 2026 8:25 AM - SEC Filing ImmunityBio secures $100 million in financing with debt conversion March 31, 2026 7:31 AM - StreetInsider ImmunityBio Strengthens Balance Sheet with $100 Million of Financing Transactions Including $75 Million of Non-Dilutive Financing to Support Global Expansion and Advancement of Broader Immunotherapy P March 31, 2026 7:30 AM - BizWire ImmunityBio ALERT: $IBRX Investors Who Lost Money Should Contact Block & Leviton By May 26th To Potentially Recover Losses March 30, 2026 3:22 PM - StreetInsider ImmunityBio bladder cancer trial meets statistical power requirements March 26, 2026 7:30 AM - StreetInsider ImmunityBio Confirms Statistical Power in Pivotal Randomized BCG-Naïve NMIBC Trial to Detect Clinically Meaningful Differences Between ANKTIVA® Plus BCG Versus BCG Alone; Supplemental BLA Submission March 26, 2026 7:30 AM - BizWire BTIG on Immunitybio Inc (IBRX): FDA warning letter issue 'likely resolvable,' selloff a buying oppty March 24, 2026 12:52 PM - StreetInsider ImmunityBio shares plunge after FDA warning over misleading ads March 24, 2026 10:44 AM - StreetInsider FDA issues warning letter to ImmunityBio over misleading ANKTIVA ads March 24, 2026 9:27 AM - StreetInsider ImmunityBio receives approval for ANKTIVA in Macau for bladder cancer March 20, 2026 1:08 PM - StreetInsider ImmunityBio Announces Approval in Macau SAR, China for ANKTIVA® in BCG-Unresponsive NMIBC with CIS ± Papillary Tumors March 20, 2026 1:08 PM - BizWire NCCN updates bladder cancer guidelines to include ImmunityBio's ANKTIVA March 17, 2026 7:31 AM - StreetInsider ImmunityBio Announces NCCN® Clinical Practice Guidelines in Oncology Have Been Updated to Include ANKTIVA® Plus BCG for Patients With BCG-Unresponsive NMIBC With Papillary-Only Disease March 17, 2026 7:30 AM - BizWire ImmunityBio completes NK cell manufacturing programs with 74 subjects March 13, 2026 7:30 AM - StreetInsider ImmunityBio Achieves Milestone with Large-Scale NK Cell Production and Cryopreservation from Over 60 Healthy and Cancer Donors March 13, 2026 7:30 AM - BizWire BTIG Assumes Immunitybio Inc (IBRX) at Buy March 11, 2026 4:06 PM - StreetInsider ImmunityBio resubmits cancer treatment application to FDA March 9, 2026 7:31 AM - StreetInsider ImmunityBio Announces Resubmission of Supplemental BLA to the FDA for ANKTIVA® Plus BCG in BCG-Unresponsive NMIBC with Papillary Disease Following Agency Review of Additional Data March 9, 2026 7:30 AM - PR NewsWire Full Article List